Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kyprolis in metastatic castration-resistant prostate cancer
NCT02047253Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Apr 2014
- Primary completion
- Jun 2017
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by University of Alabama at Birmingham. Started Apr 2014; status: completed.
02
Drugs
carfilzomib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02047253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047253.